1. Mok, TS, Wu, YL, Thongprasert, S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361: 947–957.
Google Scholar | Crossref | Medline | ISI2. Planchard, D, Popat, S, Kerr, K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2018; 29: iv192–iv237.
Google Scholar | Crossref3. Hanna, NH, Robinson, AG, Temin, S, et al. Therapy for Stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J Clin Oncol 2021; 39: 1040–1091.
Google Scholar | Crossref | Medline4. Planchard, D, Popat, S, Kerr, K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Updated version published 15 September 2020 by the ESMO Guidelines Committee, https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer (2020, accessed 25 September 2020).
Google Scholar5. Sequist, LV, Yang, JC, Yamamoto, N, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol 2013; 31: 3327–3334.
Google Scholar | Crossref | Medline | ISI6. Wu, YL, Zhou, C, Liam, CK, et al. First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non-small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26: 1883–1889.
Google Scholar | Crossref | Medline | ISI7. Zhou, C, Wu, YL, Chen, G, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011; 12: 735–742.
Google Scholar | Crossref | Medline | ISI8. Oxnard, GR, Arcila, ME, Sima, CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res 2011; 17: 1616–1622.
Google Scholar | Crossref | Medline | ISI9. Yu, HA, Arcila, ME, Rekhtman, N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res 2013; 19: 2240–2247.
Google Scholar | Crossref | Medline | ISI10. Arcila, ME, Oxnard, GR, Nafa, K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res 2011; 17: 1169–1180.
Google Scholar | Crossref | Medline | ISI11. Jenkins, S, Yang, JC, Janne, PA, et al. EGFR mutation analysis for prospective patient selection in two phase II registration studies of osimertinib. J Thorac Oncol 2017; 12: 1247–1256.
Google Scholar | Crossref | Medline12. Akamatsu, H, Delmonte, A, John, T, et al. 421P EGFR mutation analysis for prospective patient (pt) selection in AURA3 Phase III trial of osimertinib vs platinum-pemetrexed (plt-pem) in pts with EGFR T790M positive advanced non-small cell lung cancer (NSCLC). Ann Oncol 2017; 28: x124–x143.
Google Scholar | Crossref13. Li, W, Ren, S, Li, J, et al. T790M mutation is associated with better efficacy of treatment beyond progression with EGFR-TKI in advanced NSCLC patients. Lung Cancer 2014; 84: 295–300.
Google Scholar | Crossref | Medline | ISI14. Kuiper, JL, Heideman, DA, Thunnissen, E, et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 2014; 85: 19–24.
Google Scholar | Crossref | Medline15. Sun, JM, Ahn, MJ, Choi, YL, et al. Clinical implications of T790M mutation in patients with acquired resistance to EGFR tyrosine kinase inhibitors. Lung Cancer 2013; 82: 294–298.
Google Scholar | Crossref | Medline16. Wu, SG, Liu, YN, Tsai, MF, et al. The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients. Oncotarget 2016; 7: 12404–12413.
Google Scholar | Crossref | Medline17. Cross, DA, Ashton, SE, Ghiorghiu, S, et al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov 2014; 4: 1046–1061.
Google Scholar | Crossref | Medline | ISI18. Colclough, N, Chen, K, Johnström, P, et al. Preclinical comparison of the blood-brain barrier permeability of osimertinib with other EGFR TKIs. Clin Cancer Res 2020: 189–201.
Google Scholar19. Soria, JC, Ohe, Y, Vansteenkiste, J, et al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N Engl J Med 2018; 378: 113–125.
Google Scholar | Crossref | Medline | ISI20. Reungwetwattana, T, Nakagawa, K, Cho, BC, et al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non–small-cell lung cancer. J Clin Oncol 2018; 36: 3290–3297.
Google Scholar | Crossref21. Ramalingam, SS, Vansteenkiste, J, Planchard, D, et al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N Engl J Med 2020; 382: 41–50.
Google Scholar | Crossref | Medline22. Mok, TS, Wu, Y-L, Ahn, M-J, et al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N Engl J Med 2017; 376: 629–640.
Google Scholar | Crossref | Medline | ISI23. Wu, YL, Ahn, MJ, Garassino, MC, et al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized phase III trial (AURA3). J Clin Oncol 2018; 36: 2702–2709.
Google Scholar | Crossref | Medline24. Nadler, E, Pavilack, M, Espirito, JL, et al. Observational study of treatment patterns in patients with epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer after first-line EGFR-tyrosine kinase inhibitors. Adv Ther 2020; 37: 946–954.
Google Scholar | Crossref | Medline25. Li, Y, Appius, A, Pattipaka, T, et al. Real-world management of patients with epidermal growth factor receptor (EGFR) mutation-positive non-small-cell lung cancer in the USA. PLoS ONE 2019; 14: e0209709.
Google Scholar | Crossref | Medline26. Garg, A, Batra, U, Choudhary, P, et al. Clinical predictors of response to EGFR-tyrosine kinase inhibitors in EGFR-mutated non-small cell lung cancer: a real-world multicentric cohort analysis from India. Curr Probl Cancer 2020; 44: 100570.
Google Scholar | Crossref | Medline27. Cheng, Y, Wang, Y, Zhao, J, et al. Real-world EGFR testing in patients with stage IIIB/IV non-small-cell lung cancer in North China: a multicenter, non-interventional study. Thorac Cancer 2018; 9: 1461–1469.
Google Scholar | Crossref | Medline28. Isobe, H, Mori, K, Minato, K, et al. Real-world practice patterns for patients with advanced non-small cell lung cancer: multicenter retrospective cohort study in Japan. Lung Cancer 2017; 8: 191–206.
Google Scholar | Medline29. Reale, ML, Chiari, R, Tiseo, M, et al. Be-TeaM: an Italian real-world observational study on second-line therapy for EGFR-mutated NSCLC patients. Lung Cancer 2020; 140: 71–79.
Google Scholar | Crossref | Medline30. Pluzanski, A, Krzakowski, M, Kowalski, D, et al. Real-world clinical outcomes of first-generation and second-generation epidermal growth factor receptor tyrosine kinase inhibitors in a large cohort of European non-small-cell lung cancer patients. ESMO Open 2020; 5: e001011.
Google Scholar | Crossref | Medline31. Vavalà, T, Follador, A, Tiseo, M, et al. BE-POSITIVE: beyond progression after tyrosine kinase inhibitor in EGFR- positive non small cell lung cancer patients: results from a multicenter Italian observational study. Lung Cancer 2016; 95: 73–81.
Google Scholar | Crossref | Medline32. Chiang, AC, Fernandes, AW, Pavilack, M, et al. EGFR mutation testing and treatment decisions in patients progressing on first- or second-generation epidermal growth factor receptor tyrosine kinase inhibitors. BMC Cancer 2020; 20: 356.
Google Scholar | Crossref | Medline33. Ryska, A, Buiga, R, Fakirova, A, et al. Non-small cell lung cancer in countries of Central and Southeastern Europe: diagnostic procedures and treatment reimbursement surveyed by the Central European Cooperative Oncology Group. Oncologist 2018; 23: e152–e158.
Google Scholar | Crossref | Medline34. Remon, J, Menis, J, Hasan, B, et al. The APPLE trial: feasibility and activity of AZD9291 (osimertinib) treatment on positive plasma T790M in EGFR-mutant NSCLC patients. Clin Lung Cancer 2017; 18: 583–588.
Google Scholar | Crossref | Medline35. Brown, PD, Ballman, KV, Cerhan, JH, et al. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 2017; 18: 1049–1060.
Google Scholar | Crossref | Medline